Early results encourage Pluristem as it advances mesenchymal cell therapies
This article was originally published in Scrip
Executive Summary
Buoyed by outcomes described by one patient's doctor as a "medical miracle," Pluristem Therapeutics is carefully weighing its options for the specific bone marrow-related indication it will pursue for its PLX (PLacental eXpanded) cell therapy - mesenchymal cells harvested from allogeneic (donor-derived) placental tissue that are attached to therapeutic proteins to induce an immune response.